Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Crinetics Pharmaceuticals Inc (CRNX)

Crinetics Pharmaceuticals Inc (CRNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,499,778
  • Shares Outstanding, K 94,892
  • Annual Sales, $ 1,040 K
  • Annual Income, $ -298,410 K
  • EBIT $ -478 M
  • EBITDA $ -490 M
  • 60-Month Beta 0.20
  • Price/Sales 4,290.69
  • Price/Cash Flow N/A
  • Price/Book 4.16

Options Overview Details

View History
  • Implied Volatility 76.58% (-4.50%)
  • Historical Volatility 47.58%
  • IV Percentile 93%
  • IV Rank 74.66%
  • IV High 89.00% on 09/24/25
  • IV Low 40.01% on 08/15/25
  • Expected Move (DTE 14) 2.47 (5.28%)
  • Put/Call Vol Ratio 21.00
  • Today's Volume 484
  • Volume Avg (30-Day) 630
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 11,284
  • Open Int (30-Day) 10,414
  • Expected Range 44.21 to 49.14

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.34
  • Number of Estimates 8
  • High Estimate -1.20
  • Low Estimate -1.54
  • Prior Year -0.88
  • Growth Rate Est. (year over year) -52.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
38.81 +20.24%
on 11/07/25
48.62 -4.01%
on 12/04/25
+4.14 (+9.73%)
since 11/05/25
3-Month
33.19 +40.61%
on 09/11/25
48.62 -4.01%
on 12/04/25
+11.06 (+31.06%)
since 09/05/25
52-Week
24.10 +93.65%
on 04/09/25
60.34 -22.65%
on 12/11/24
-11.02 (-19.10%)
since 12/05/24

Most Recent Stories

More News
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors

SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the first patient has been dosed in the Phase 1/2 study evaluating CRN09682 in patients...

CRNX : 46.67 (-1.58%)
Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome

CAREFNDR underscores the potential clinical value of p altusotine b eyond acromegaly, and demonstrates progress in Crinetics’ commitment to addressing unmet needs in the neuroendocrine tumor community...

CRNX : 46.67 (-1.58%)
Metabolic Reset: Cell Therapies and Novel Drugs Reshape Chronic Disease Market

VANCOUVER – Baystreet.ca News Commentary – The metabolic disorder therapeutics market projects growth to $120.7 billion by 2030 as biotechnology firms pioneer organ-level treatments addressing diabetes,...

AVAI : 0.2875 (-2.58%)
TNDM : 20.92 (+1.01%)
CRNX : 46.67 (-1.58%)
MDGL : 577.30 (-1.52%)
ALT : 5.24 (-1.32%)
Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on November 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified...

CRNX : 46.67 (-1.58%)
Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

       PALSONIFY™ (Paltusotine) Launched in the U.S. with Encouraging Early Feedback from Patients and Physicians, and Positive Reimbursement Trends        Reiterates Cash Burn of $340-370M...

CRNX : 46.67 (-1.58%)
Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting

SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced three abstracts from its clinical development programs will be presented at the upcoming...

CRNX : 46.67 (-1.58%)
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on October 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified...

CRNX : 46.67 (-1.58%)
Piper Sandler Sticks to Its Buy Rating for Crinetics Pharmaceuticals (CRNX)

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Crinetics Pharmaceuticals, with a price target of $97.00. The company’s shares closed yesterday at $42.50.Elevate...

CRNX : 46.67 (-1.58%)
Crinetics Pharmaceuticals (CRNX) Gets a Buy from Cantor Fitzgerald

Cantor Fitzgerald analyst Joshua Schimmer maintained a Buy rating on Crinetics Pharmaceuticals yesterday and set a price target of $90.00. The company’s shares closed yesterday at $41.61.Elevate Your...

CRNX : 46.67 (-1.58%)
Stocks Finish Higher as Core PCE Prices Match Expectations

The S&P 500 Index ($SPX ) (SPY ) on Friday closed up +0.59%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.65%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.44%. December E-mini...

AMAT : 268.00 (-0.53%)
MPC : 190.53 (+0.20%)
PCAR : 110.33 (+1.69%)
MRK : 99.72 (-1.16%)
SLB : 38.46 (+0.89%)
CNXC : 37.61 (+1.76%)
TXN : 182.54 (+1.34%)
$IUXX : 25,692.05 (+0.43%)
AMGN : 329.89 (-3.02%)
PFE : 26.03 (+1.28%)
ZNH26 : 112-165s (-0.18%)
OXY : 42.43 (-0.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

CRINETICS PHARMACEUTICALS is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. CRINETICS PHARMACEUTICALS is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 48.63
2nd Resistance Point 48.23
1st Resistance Point 47.45
Last Price 46.67
1st Support Level 46.27
2nd Support Level 45.87
3rd Support Level 45.09

See More

52-Week High 60.34
Last Price 46.67
Fibonacci 61.8% 46.50
Fibonacci 50% 42.22
Fibonacci 38.2% 37.94
52-Week Low 24.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar